Biohldg sudah 2 tahun xda naik 30 sen apa bikin jual daun ketum la u mmg untung mahh,,investor hari2 tggu bisnes u smpai maybank ckp u company Ada bgus,,lanncioo bisnes apa u bikin tipu org mys
Ginduchti Bankers collecting at 19-20cts level and sell all at 22-22.5cts , simple as that
Reasonable point, but would also like to point out that not much retailers/traders are buying here due to lack of corporate news/promotions, unstable local scene and just general low market sentiment.
In that case think likely more tickets end up back in the bankers/market makers' hands than being successfully sold to outsiders..
i have a friend's friend who attended a briefing hosted by management just now...according to the boss, the revnue from this project is easily more than 200 millions....5% margin also more than 10 million already.....for a small company like bio aplha, it is like making next 5 years profit...easily can limit up few times
poor country..WHO pay for testing and vaccine..no need to worry. Company in international trade knows how to protect their interest. Sudan cannot pay kira bad debt so Bio can claim sudan and send some of the investor who talk talk t o stay there..lol
KUALA LUMPUR (July 28): Bioalpha Holdings Bhd has partnered a laboratory in South Sudan to undertake a Covid-19 testing programme at the border entry points in the country.
The health supplement group said in a filing that its wholly-owned subsidiary Bioalpha (HK) Ltd (Bioalpha HK) had entered into a memorandum of agreement (MoA) with Crawford Laboratory of the Republic of South Sudan to exclusively undertake the Covid-19 testing programme.
The mandate involves installation of testing facilities, as well as the provision of testing products and services at border entry points in the country to screen all inbound travellers to South Sudan at these locations to prevent cross-border infections.
According to Bioalpha, this collaboration is part of the initiative by the East African Community (EAC) to make available Covid-19 testing products and services to the 180 million population in six partner countries.
Apart from South Sudan, the other countries are Kenya, Rwanda, the United Republic of Tanzania, the Republic of Uganda and the Republic of Burundi.
Crawford Laboratory is principally involved in the provision of Covid-19 testing activities in South Sudan and is currently the only organisation in the country offering online applications for Covid-19 tests.
Under the MoA, Bioalpha HK will supply the necessary equipment and the training required to properly utilize the said equipment for the purpose of the Covid-19 testing programme.
Bioalpha HK will supply 100,000 test kits per month along with its consumables, and the testing cost to be charged to travellers is at approximately US$20 (RM85) for locals and US$50 (RM212) for foreigners.
Meanwhile, Crawford Laboratory will manage the testing facilities and liaise with the necessary authorities within South Sudan to ensure all inbound travellers to the country via the Nimule and Juba International Airport are compulsorily required to take the Covid-19 test under the programme.
It will also obtain the necessary regulatory approvals required for the programme.
The MoA will come into effect on the date of signing and will remain in effect for a period of two years from the date of signing of the MoA subject to a further renewal based on both parties' mutual agreement.
Bioalpha said the MoA enables the company to widen its revenue streams to include the distribution of Covid-19 screening equipment and products to nations under the EAC, starting with South Sudan, which has a population of 11 million people.
“In addition, this programme would also pave way and serve as a platform for Bioalpha to expand the delivery of other healthcare and pharmaceutical products and services to South Sudan as well as other partner states under the EAC,” it said, adding that this opens up a whole new market for Bioalpha as it establishes its presence in the EAC nations.
The MoA is expected to contribute positively towards the future earnings of Bioalpha, the company said.
Bioalpha closed 0.5 sen or 2.27% higher at 22.5 sen today, valuing the group at RM260.59 million.
Vaccine is one dose or two dose but test kits maybe require more than as for checking purpose, guess the demand is there and there are a huge demand that will profit to bioholding. Let see how coming QR will reflected on it
Seems like a lot of people sell on news, but not heavy sell down, seems good, Technical is forming and now additional with news now. Sooner or later sure goreng one wave. Good timing to invest some share in it.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
mawiLegend
152 posts
Posted by mawiLegend > 2021-07-23 13:47 | Report Abuse
Biohldg sudah 2 tahun xda naik 30 sen apa bikin jual daun ketum la u mmg untung mahh,,investor hari2 tggu bisnes u smpai maybank ckp u company Ada bgus,,lanncioo bisnes apa u bikin tipu org mys